| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1012: Avapritinib for treating advanced systemic mastocytosis |
|
Medicine details |
|
| Medicine name | avapritinib (Ayvakyt®) |
| Formulation | 25 mg, 50 mg, 100 mg, 200 mg film-coated tablet |
| Reference number | 4485 |
| Indication | Monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy |
| Company | Blueprint Medicines |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/09/2024 |
| NICE guidance | TA1012: Avapritinib for treating advanced systemic mastocytosis |